Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

NCT04284761 is registered in ClinicalTrials.gov with Alessa Therapeutics Inc. as lead sponsor.

NCT NCT04284761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04284761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer
Lead sponsor
Alessa Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 11, 2020
Completion date
May 3, 2023
Enrollment
17 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lower urinary tract symptoms, prostate adenocarcinoma